Somewhere in the next six weeks, a client is going to mention the dental work they have been putting off, or the hospital stay that cost them more out of pocket than they expected. You will know there is a product that addresses it. And a voice in the back of your head — put there by a compliance slide you half-remember — will say you can't bring that up, that's cross-selling. That voice is working from half a sentence.

CMS does use the word "cross-selling," and it does prohibit it. But the regulation defines it narrowly, and the products most agents are afraid to mention are on the other side of the line. Worse, the rules governing how you document that conversation changed on October 1, 2026, two weeks before AEP opened, so the slide you are remembering may be describing a requirement that no longer exists.

Is Cross-Selling Prohibited in a Medicare Appointment?

Non-health-care-related products are prohibited. Health-care-related products are not — they are gated by the Scope of Appointment. That distinction is the whole thing, and it is written plainly in the regulation.

At 42 CFR § 422.2263(b)(4), in the list of things an MA organization may not do in marketing: "Market non-health care related products to prospective enrollees during any MA sales activity or presentation. This is considered cross-selling and is prohibited." The Part D rule at § 423.2263(b)(4) is word-for-word the same, with "Part D" in place of "MA."

Read it twice, because the operative phrase is non-health care related. The regulation does not say "other products." It does not say "anything you are not appointed for under this plan." It names a category, and a dental plan, a vision plan, a hearing plan and a hospital indemnity policy are not obviously in it. The prohibition that does reach health-related products is somewhere else entirely, and it is a documentation rule rather than a ban.

What the Scope of Appointment Actually Controls

Three paragraphs at 42 CFR § 422.2264(c)(3)(iii) govern what can be discussed in a personal marketing appointment. They are short enough to know by heart:

  • (A) You may not market any health care related product "beyond the scope agreed upon by the beneficiary." That scope is documented in a Scope of Appointment, a business reply card, or a request to receive additional information, and it is valid for 12 months following the beneficiary's signature date or the date of their initial request for information.
  • (B) You may not market additional health related lines of plan business that were not identified before the appointment "without a separate Scope of Appointment" identifying those additional lines. That second SOA is also valid for 12 months from signature.
  • (C) You may not market non-health related products, "such as annuities."

So the structure is: health-related products are available to you if they are in scope, and the fix for "it isn't in scope" is a second SOA rather than silence. Non-health-related products are off the table during the appointment regardless of what anybody signs.

Two details worth having right. First, the regulation does not prescribe a form. § 422.2264(c)(3)(i) requires only that the plan, agent or broker "agree upon and record the Scope of Appointment with the beneficiary(ies)," and that it "must be in writing for in-person personal marketing appointments." The familiar checkbox sheet with boxes for Part D, MA and Cost plans, dental/vision/hearing and hospital indemnity is a model artifact your carrier or FMO distributes, not the rule itself — which is why versions differ and why you should be using the current one from the carrier whose business you are writing. Second, the obligation sits on you individually: § 422.2274(b)(3) requires agents and brokers who represent MA organizations to "secure and document a Scope of Appointment prior to a personal marketing appointment," and § 422.2274(c)(9)(ii) makes the plan responsible for confirming you did it — for every appointment, "including telephonic and walk-in."

Three things changed for this AEP, effective October 1

CMS's contract year 2027 final rule — published in the Federal Register on April 6, 2026, effective June 1, 2026, with its marketing provisions applying to all contract year 2027 marketing beginning October 1, 2026 — rewrote the paragraphs above. If your compliance training predates it, three items are stale:

The 48-hour Scope of Appointment waiting period is gone. The current text of § 422.2264(c)(3)(i) requires the SOA to be agreed and recorded "prior to the personal marketing appointment" and says nothing about 48 hours. The phrase does not appear anywhere in subpart V of Part 422 or Part 423 as the regulation now stands.

You may now collect a Scope of Appointment at an educational event. The rule's amendment to § 422.2264(c)(1)(ii)(D) replaced the phrase "Cards, but not including Scope" with "Cards and Scope" — a four-word edit that reverses the old prohibition. Educational events still may not include sales presentations or plan applications.

The separation between an educational event and a marketing event is now notice, not a clock. Where a marketing event directly follows an educational one, § 422.2264(c)(2)(i) requires that attendees be told the educational event is ending and be given "a sufficient opportunity to leave" before marketing begins.

Which Products Sit On Which Side of the Line?

The honest answer is that the regulation draws the line without fully defining it, and you should treat the boundary cases as compliance questions rather than judgment calls made in a client's kitchen.

What the regulation names: annuities, as the example of a non-health-related product under § 422.2264(c)(3)(iii)(C). That is the only product the text names.

What the model Scope of Appointment forms carriers distribute treat as health-related lines: stand-alone Part D, Medicare Advantage and Cost plans, dental/vision/hearing products, and hospital indemnity products — with Medicare Supplement appearing as a separate box on many versions. If a product has its own box on the SOA your carrier gives you, the carrier has answered the in-scope question for you; check the box, or do not discuss it.

What nobody has defined for you: final expense life, critical illness, cancer and accident policies do not appear in the regulation's text, and whether a given one is "health care related" is not something the regulation resolves. Life insurance with a cash or investment component sits closer to the annuity example than to a dental plan. The cost of guessing wrong here is a complaint on a recorded appointment, so the move is to ask your FMO's compliance desk once, in writing, and then apply the answer consistently rather than deciding per client.

One more thing the regulation permits that agents tend to miss: at a personal marketing appointment you may "review the individual needs of the beneficiary including, but not limited to, health care needs and history, commonly used medications, and financial concerns" — § 422.2264(c)(3)(ii)(D). Understanding that a client has an unexpected hospital bill in their recent past is not marketing anything. It is the fact-find the regulation explicitly contemplates. What you do next is where the scope rules apply.

The TPMO Disclaimer Changed Too

If you are an independent agent selling for more than one MA organization, you are a third-party marketing organization under § 422.2260, and the standardized disclaimer at § 422.2267(e)(41) is yours to deliver. The CY2027 rule revised when: it must now be "verbally conveyed during sales calls prior to the discussion of any benefits." Not within some number of seconds — before benefits come up.

That timing matters more in a multi-product conversation than a single-product one, because a call that drifts from a dental question into plan benefits has crossed the line that triggers it. The disclaimer is also required electronically in email and chat, prominently on TPMO websites, and in print and television materials.

What's Smart Is a Different Question From What's Allowed

Compliance tells you whether you may have the conversation. It does not tell you whether you should, and the regulation has an opinion about that too.

§ 422.2274(c)(13) requires MA organizations to ensure no provision of a contract with an agent, broker or TPMO "has a direct or indirect effect of creating an incentive that would reasonably be expected to inhibit an agent or broker's ability to objectively assess and recommend which plan best fits the health care needs of a beneficiary." That rule is addressed to the carrier, but the behavior it describes is yours. If the ancillary attachment is what makes a particular MA recommendation attractive to you, the order of operations has gone wrong, and that is visible in a complaint review in a way that is hard to explain away.

The economics are worth being plain about, because they cut both ways. Medicare compensation is capped: CMS sets a fair market value limit under § 422.2274 and renewal compensation at 50 percent of it, which is why the published 2027 figures are what they are — caps the carrier may pay up to, never amounts an agent is guaranteed to earn, as our compensation breakdown lays out. Ancillary products written with a carrier outside that enrollment are not priced by that rule. The number is the carrier's, it varies by product and by market, and your FMO can tell you what it is for a specific contract — which is exactly the kind of question to ask before you build a strategy around it, not after.

The defensible version of this business is the one where the product solves something the client actually has. An MA plan with a maximum out-of-pocket leaves real exposure below that ceiling, and a hospital indemnity policy is designed around utilization rather than premium. Dental is the benefit clients most often discover their plan covers thinly. Those are honest conversations, and they are the ones that survive a recording. The indefensible version is the one where a product gets introduced because the Medicare commission is capped and this one isn't.

The Three Mistakes That Turn Into Complaints

  • Expanding the scope mid-appointment without documenting a second SOA. § 422.2264(c)(3)(iii)(B) requires a separate Scope of Appointment for health-related lines that were not identified before the appointment. Now that the 48-hour wait is gone, the documentation is the entire requirement — so there is no excuse left for skipping it, and no cover if you do.
  • Assuming an ancillary-only appointment needs no SOA, and then discussing Medicare. The SOA obligation attaches to a personal marketing appointment for MA or Part D. Start a conversation about a dental plan, let it move to the client's Medicare Advantage options, and you are in a Medicare appointment that began without a scope. The fix is cheap: document the scope broadly at the start, including the ancillary lines, and you never have to make that call under pressure.
  • Relying on a 2022 document for a 2027 appointment. The most recent Medicare Communications and Marketing Guidelines CMS has posted is dated February 9, 2022, and it says of itself that it "has been structured to align with the regulatory requirements in 42 CFR Part 422 Subpart V and 42 CFR Part 423 Subpart V" and "should be used in conjunction with the regulatory requirements." The regulation is the thing that binds, and subpart V was last amended April 6, 2026. The MCMG also notes that plans may impose additional restrictions on their downstream entities, so your carrier's policy can be stricter than the regulation — and often is.

What To Do Before Your Next Appointment

  • Pull the current SOA from each carrier you write and check which product boxes it offers. That list is your practical scope menu, and it differs between carriers.
  • Default to documenting a broad scope. If you hold dental, vision, hearing or hospital indemnity contracts, include them when you take the SOA. An SOA is valid 12 months; a conversation you cannot have is worth nothing.
  • Get one written answer from compliance on the products the regulation does not name — final expense, cancer, critical illness, accident. Ask once, apply it everywhere.
  • Move the TPMO disclaimer earlier in your call script so it lands before any benefit comes up, not after the pleasantries.
  • Check your appointments before AEP ends, not after. If you are quoting ancillary you are not contracted to write, you are doing a fact-find for somebody else.

Where a Wider Lineup Stops Being Theoretical

Knowing what you are allowed to discuss only matters if you have something to offer when the client says yes. Benefits Life contracts across 280+ carriers in 5 lines of business, and the full granular view on our carrier roster runs to 16 lines — including the dental, vision, hearing and hospital indemnity carriers that this conversation depends on. Multi-line carriers are counted once there, so the roster is a real list rather than an inflated one.

That breadth matters most in the counties where Medicare Advantage benefits thinned for 2027. When the rich supplemental package a client liked gets trimmed, the agent who can only write the plan has one conversation available and the agent with the ancillary lines has three.

The Bottom Line

"Cross-selling is prohibited" is true and incomplete. What § 422.2263(b)(4) prohibits is marketing non-health-care-related products during a Medicare sales activity, and the regulation's named example is an annuity. Health-related ancillary products are not banned; they are gated by a Scope of Appointment that is valid for 12 months, that no longer carries a 48-hour waiting period, and that can now be collected at an educational event.

Which means the question in front of you is not really a compliance question. The compliance answer is a form you fill in correctly. The real question is whether the product you are about to introduce solves a problem the client described to you, or a problem with your own commission schedule. Agents who can tell the difference have a second product line. The ones who can't have a complaint file.